ALGORITHM, MULTIPLE MYELOMA

Estimation of survival for patients with RRMM, requires prognostic tools that define the relative risk of death after first relapse. We recently developed a risk stratification algorithm (RSA) using real-world data from the Czech Registry of Monoclonal Gammopathies (RMG). Our RSA uses patient and disease characteristics at diagnosis and at initiation of second-line treatment (2L), and previous treatment outcomes to stratify patients based on their overall survival (OS) expectations from initiation of 2L treatment (Hajek et al. Blood 2016). The value of such an algorithm depends on its validation, but also on understanding the evidence that explains these differences in survival expectations.